Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FF 10502

Next Previous
Drug Profile

FF 10502

Alternative Names: FF-10502-01

Latest Information Update: 15 Feb 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FUJIFILM Holdings Corporation
  • Developer Strategia Therapeutics
  • Class Antineoplastics; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Lymphoma; Solid tumours

Most Recent Events

  • 15 Feb 2022 FF 10502 is still in phase I/II trials for Solid tumours and Lymphoma in USA (FUJIFILM pipeline, February 2022)
  • 05 Nov 2020 FUJIFILM Holdings Corporation completes a phase I/II trial in Lymphoma (Late-stage disease) and Solid Tumors (Late-stage disease) in the USA (IV) (NCT02661542)
  • 03 Jun 2019 Updated efficacy and adverse events data from a phase I trial in Lymphoma and Solid tumours (Late-stage disease) presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top